

Fungal urinary tract infections in pediatric age groups

Safaa M. Sultan

Northern Technical University/ Mosul/Iraq
safaahawija@gmail.com

Corresponding author: Safaa sultan, safaahawija@gmail.com

Received: 01-09-2022, Accepted: 09-09-2022, Published online: 20-09-2022

Abstract. One of the most prevalent and recurring bacterial diseases in kids is urinary tract infections (UTI). At least 8% of girls and 2% of boys are thought to suffer UTIs as children. The fungi are often linked to UTIs, and their antibiotic susceptibility patterns change over time and across various environments. To choose the best empirical antimicrobial therapy, it is crucial to understand the trends of uropathogenic antibiotic resistance in certain geographic areas. Therefore, this research assesses the causal organisms in urine samples and their antibiotic susceptibility profile among patients who visit Mosul's general outpatient department clinic. Due to space restrictions, our research primarily focused on fungus-related UTIs in children (2–12) years old. . Adult infections, reflux nephropathy, catheter-associated and nosocomial infections, medication assessment for particular antimicrobials, and viral and rickettsial infections are only a few examples of the subjects covered. The study intends to close a gap in the literature about how candiduria manifests in pediatric inpatients and outpatients. The current study's objective was to ascertain the prevalence of candiduria among kids visiting External laboratories in Mosul, Iraq. Additionally, isolates' sensitivity to several antifungal medications was taken into consideration.

Keywords: UTI, *C. albicans*, *C. Kruzi*, YEPD, Antifungal resistance

Introduction

A common cause of juvenile febrile illness, symptomatic, culture-positive UTIs are found in 7% of girls and 2% of boys by the age of six. Although there are conflicting views on the long-term effects of UTI and whether to start prophylaxis in infancy,. Untreated infections like this one have known risk factors for end-stage renal disease because they may cause future renal scarring. Therefore, there is clinical and public concern about the high rate of untreated, inadequately managed UTIs in young children[1,2]. For both sexes and at various periods of life, UTI incidence and clinical effects vary greatly. Males have UTI more often in the first three months of life, with a 5:1 sex distribution (male predominance).

By preschool age, the sex ratio is reversed, with most UTIs occurring in females[3]. The two conditions of circumcision and UTI are related. Uncircumcised newborns have a higher chance of UTI, particularly in the first year of life. In the first six months of life, uncircumcised infants have more uropathogenic colonization around the meatus than circumcised children, and 10% of UTIs are brought on by Gram-positive bacteria Staphylococci, Enterococci, and Streptococci. The most frequent reason for using long-term antibiotics is a fungus-like *Candida albicans*. , patients utilizing invasive equipment like catheters or immunocompromised individuals [4]. Although *C. albicans* causes a significant incidence of morbidity in UTIs, the mortality is modest.

But a significant death rate is seen in AIDS and systemic candidiasis patients [5,6]. Urinary tract infections (UTIs) brought on by bacteria or fungi fall into two anatomical categories: lower and upper tract infections, which may manifest as symptomatic or asymptomatic conditions[7]. Our knowledge of the incidence of candidal UTIs comes from multiple published reports in different countries throughout the world. In order to develop cutting-edge methods to treat and prevent the related disorders, it is essential to continuously monitor the pattern of the causative microorganisms [8]. Numerous investigations have shown that members of the *Candida* genus, and in particular *Candida albicans*, are the most significant opportunistic pathogenic fungus responsible for nosocomial UTIs (*C.albicans*)[9]. Numerous investigations have shown that the most notable opportunistic pathogenic fungus causing nosocomial UTIs is *Candida* species, particularly *Candida albicans* (*C.albicans*). They also grow on the exterior of the urethral opening in healthy premenopausal females. NACA yeasts and the other host flora proliferate beyond the urethral opening in healthy premenopausal females. Due to the commensal yeasts of *Candida* turning into opportunistic pathogenic bacteria in this condition, the host may get candidal UTIs [10,11]. 43 to 45 °C is the optimal temperature range for *C. krusei*. Only *C. krusei* can grow on a vitamin-free medium, although the most medically significant *Candida* spp. They need biotin for development, and some others have extra vitamin needs. [12]. The current research aims to evaluate the various characteristics of yeast and associated UTIs due to the significance of *C.albicans*-caused UTIs.

Materials and methods

Sample collection

In the current research, urine samples from 139 children visiting the Mosul external labs for children aged 2 to 13 years were obtained over two months (from February 2022 to April 2022). (87 females, 52 males). Sterilized pee bottles and bags were used to collect urine samples (when necessary). The Medical Mycology Department received 10 l of each urine sample after it had been cultivated on CHROM agar *Candida* plates; all plates were incubated for a maximum of one week at 37°C.

Yeasts identification

A direct smear from the developed colony was obtained, and microscopic analysis established it to be yeast.

As previously noted by authors[13,14], all yeast colonies were originally recognized based on color colony development on CHROM agar *Candida* and compared to industry-standard color pictures provided by the manufacturer. The germ tube test, morphology on cornmeal agar (Difco, USA), and growth at 45–47°C were used to identify colonies that were green as *C. albicans*.

C. krusei produced large pinkish colonies on CHROM agar *Candida*, and its morphology on cornmeal agar was pseudohyphae with elongate blastoconidia similar to the treelike form. Pink colonies were confirmed based on their morphology on cornmeal agar as *C. glabrata* (small yeasts with budding cells without- any pseudohyphae).

Susceptibility test for antifungals

Disk diffusion techniques were employed in the current study's susceptibility test[15]. Numerous antifungal drugs, including miconazole (10 mg), nystatin (100 U), clotrimazole (50 mg), fluconazole (100 mg), and Griseofulvin (20 mg) The susceptibility of disks (Liofilchem Bacteriology Products, Italy) was examined.

Germ tube method

In this study, a swab from a *Candida* sample was combined with 5.0 ml of serum, incubated at 37°C for a couple of hours, and then observed under a microscope. We discovered that only *C. albicans* can form germ tubes at 39°C in serum-free YEPD media (1% (w/v) yeast extract, 2% (w/v) peptone, and 2% (w/v) dextrose).

Results and discussion Identification of injury

Data from Figure 1 showed that 59.71% of kids (46.76% of girls and 12.95% of boys) had urinary tract infections.

Patients who were enlisted had a high frequency of *Candida*. Figures 2 and 3 show how common urinary tract infections are, with *Candida* being the most commonly identified pathogen in our investigation; when it was discovered that the adversary only affected males, there were 18 instances, and there were no infections with *C. kruzi*. Most infections in females—42—were caused by the *C. albicans* yeast, whereas the number of cases caused by the *C. kruzi* yeast was 23.

Diagrams 4 and 5.




Figure 1. Identification of injury




Figure 2. infected in females




Figure 3. infected in males




Figure 4. C. albicans yeast




Figure 5. C. kruzi yeast

Antifungal resistance

The results indicated the relative resistance of most yeast isolates under study to most antibiotics used. Table 1 shows that Nystatin was one of the most effective antibiotics with the appearance of the highest inhibition zones, where the diameters of inhibition zones were between (17-30) mm. This result was consistent with what was reached [16]; it was found that Nystatin was one of the best antagonists in inhibiting the growth of *Candida*. As for the anti- ketoconazole, the inhibition diameters ranged between (16-22) mm, and it had a clear effect, as it inhibited 62% of the isolated yeast species. Clotrimazole ranked third in terms of the ability to inhibit the growth of *Candida* species, and this antibiotic was efficient in inhibiting the growth of *Candida*. As for the antibiotic, Fluconazole, it came in fourth place in inhibiting the growth of *Candida* species under study, where the percentages of inhibition were 15.6%, and this is the result. It may be due to the frequent use of antibiotics, as well as the development of the type of resistance that these isolates possess against most of the antibiotics used, Sibanda and Okoh (and finally, the anti- Griseofulvin) ranked last in the growth inhibition of the *Candida* species under study, where the percentages of inhibition were 100% as the same observed by [17], as the anti-Griseofulvin did not show any effect on *Candida* yeast, it did not show growth inhibition within the concentrations used, and therefore our results agreed with the findings of [18] which found that this drug has a narrow-term effect. The influence of *Candida* is not present in the direction of fungi. Practical and clinical factors determine which antibacterial medication will be used empirically to treat juvenile UTI. Importantly, when selecting the agent to employ before culture and sensitivity findings are available, it is important to take into account regional differences in fungal susceptibility and resistance patterns to certain antibiotics.

Additionally, resistance may be impacted by current and past antifungal usage. [19]. Since concurrent fungi are at a 10% risk, systemic antifungal medication is often started at the outset of treatment. [20].

Assuming that risk factors have been as effectively removed or controlled, Fluconazole is the medicine of choice for treating cystitis brought on by most *Candida* species owing to its in vitro activity and pharmacokinetics, excluding rare resistant yeasts like *Candida krusei* and *Candida glabrata*.

A dose of 200-400 mg given orally once a day for two weeks should be enough since fluconazole, which is highly water-soluble, is mostly removed in the urine as an active medicine [21,22].

Most patients with symptomatic *Candida* cystitis should begin therapy with Fluconazole, without a doubt. By the age of six, 7% of girls and 2% of boys have a symptomatic, culture-positive UTI, which is a prevalent cause of pediatric febrile illness. Although there are divergent opinions on the long-term consequences of UTI, The general goals of therapy for pediatric UTI remain symptom relief and the position of prevention., avoidance of both immediate and long-term consequences, including systemic infection. There is strong evidence of past and developing resistance patterns, thus it is crucial to rationalize prescription patterns by understanding sensitivities and reevaluating empirical antibiotic selections. To enhance therapeutic impact, local formularies should take regional patterns of resistance into account together with the best available research on the length of time and antibiotic choice, To enhance therapeutic impact, local formularies should take regional patterns of resistance into account together with the best available research on the length of time and antibiotic choice. Urinary tract anomalies, prematurity, male gender, VUR, lack of circumcision, repeated invasive surgeries, intravascular catheters, parenteral feeding, and a lengthy nursery course are risk factors for the development of UTI in neonates [23,24]. Multicenter research looked at UTI clinical and demographic aspects [18]. They discovered no connection between the male gender and UTI and circumcision. Levy and co. It has been shown that preterm newborns are more likely to have UTIs than term infants [25], and uncircumcised males are more likely to develop UTIs [26]. Our research has several limitations. Due to the fact that every kid in our study had been circumcised, we were unable to compare this. *Candida Albicans* and *Candida Kruzi* were the most prevalent pathogens in the present investigation among our newborns with UTI Clinical. UTI symptoms in children might be quite different from one another. Most people have mild or ambiguous symptoms, such as poor eating, diarrhea, fever, vomiting, irritability, and tiredness [27].

Table 1. Antifungal resistance

Anti-type	<i>C.albicans</i>	<i>C. kruzi</i>
Nystatin	30mm	17mm
Ketoconazole	22mm	16mm
Clotrimazole	20mm	15mm
Fluconazole	18mm	12mm
Griseofulvin	0mm	0mm

Germ tube

C. albicans is distinguished from other Candida species by us.

None of the clinically isolated Candida species other than *C. albicans* produced germ tubes in YEPD at 39° C for 1 hour, but all of the clinically isolated *C. albicans* strains did.

Therefore, a strategy for the quick and easy detection of *C. albicans* in clinical labs might be based on the specific germ tube development of *C. albicans* produced by high temperatures (39° C) in YEPD.




Figure 6. identify *C. albicans*

Acknowledgments

The author admits gratitude to the Medical Laboratory Technologies Laboratory at the Northern Technical University, for supporting the completion of the study requirements.

References

- [1] KAUFFMAN, Carol A. Diagnosis and management of fungal urinary tract infection. *Infectious Disease Clinics*, 2014, 28.1: 61-74.
- [2] Mohammed, G. F., Sultan, S. M., & Sadullah, Y. Q. (2020). The relationship between Creatinine and patients with Renal Failure associated with anemia. *Research J. Pharm. and Tech*, 13(4), 1633-1635.
- [3] Velde, G. V., Kucharíková, S., Dijck, P. V., & Himmelreich, U. (2014). Bioluminescence imaging of fungal biofilm development in live animals. In *Bioluminescent Imaging* (pp. 153-167). Humana Press, Totowa, NJ.
- [4] Dorsaz, S., Coste, A. T., & Sanglard, D. (2017). Red-shifted firefly luciferase optimized for *Candida albicans* in vivo bioluminescence imaging. *Frontiers in microbiology*, 8, 1478.
- [5] ALSUWAYFEE, K. I., AHMED, M., & MOHAMMED, Q. N. (2020). Congenital heart disease and pulmonary hypertension among Down syndrome pediatric patients. *Annals of the College of Medicine, Mosul*, 42(1), 50-56.
- [6] Mayer, F. L., Wilson, D., & Hube, B. (2013). *Candida albicans* pathogenicity mechanisms. *Virulence*, 4(2), 119-128.
- [7] Van Dyck, K., Rogiers, O., Vande Velde, G., & Van Dijck, P. (2020). Let's shine a light on fungal infections: A noninvasive imaging toolbox. *PLoS Pathogens*, 16(3), e1008257
- [8] Mahish, P. K., Chandrawanshi, N. K., Kunjam, S., & Jadhav, S. K. (2021). Opportunities in the Living Lights: Special Reference to Bioluminescent Fungi. *Energy: Crises, Challenges and Solutions*, 191-207.
- [9] Rosowski, E. E., Knox, B. P., Archambault, L. S., Huttenlocher, A., Keller, N. P., Wheeler, R. T., & Davis, J. M. (2018). The zebrafish as a model host for invasive fungal infections. *Journal of Fungi*, 4(4), 136.
- [10] Fisher, J. F., Kavanagh, K., Sobel, J. D., Kauffman, C. A., & Newman, C. A. (2011). *Candida* urinary tract infection: pathogenesis. *Clinical Infectious Diseases*, 52(suppl_6), S437-S451.
- [11] Almeida, A. A. D., Mesquita, C. S. S., Svidzinski, T. I. E., & Oliveira, K. M. P. D. (2013). Antifungal susceptibility and distribution of *Candida* spp. isolates from the University Hospital in the municipality of Dourados, State of Mato Grosso do Sul, Brazil. *Revista da Sociedade Brasileira de Medicina Tropical*, 46, 335-339.
- [12] Fisher, J. F., Kavanagh, K., Sobel, J. D., Kauffman, C. A., & Newman, C. A. (2011). *Candida* urinary tract infection: pathogenesis. *Clinical Infectious Diseases*, 52(suppl_6), S437-S451
- [13] Mahmoudabadi, A. Z., Keradmand, A. R., & Enayatollahi, N. (2009). Frequency of candiduria in inpatients and outpatients in department of Urology, Golestan Hospital, Ahvaz, Iran. *Iranian journal of kidney diseases*, 3(2), 114-115.
- [14] Mahmoudabadi, A. Z., Najafyan, M., & Alidadi, M. (2010). Clinical study of *Candida* vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. *Pak J Med Sci*, 26(3), 607-10.
- [15] Alhadedy, S. S., & Al-Doory, M. I. (2018). Isolation and Diagnosis of *Candida Albicans* from the Vaginal Canal and Test the Effect of Water Extract of Turmeric Inhibitor for Growth outside the Organism. *Al-Kitab Journal for Pure Sciences*, 2(1).
- [16] Alhadedy, S. S., & Al-Doory, M. I. (2018). Isolation and Diagnosis of *Candida Albicans* from the Vaginal Canal and Test the Effect of Water Extract of Turmeric Inhibitor for Growth outside the Organism. *Al-Kitab Journal for Pure Sciences*, 2(1).
- [17] Aldory, M. E., Ali, F. F., & Sultan, S. M. (2018). Effective of Watery and Alcoholic Extract of Frankincense on the *Candida Albicans* Fungus. *International Journal of Pharmaceutical Research & Allied Sciences*, 7(3).
- [18] Alkashab, F. M., Fathy, R. G., & Sultan, S. M. (2020, September). Effects of *Rosmarinus Officinalis* Plant Extract on *Trichomonas Vaginalis* Parasites and *Candida albicans* under Laboratory Conditions: An Experimental Study. In *IMDC-SDSP 2020: Proceedings of the 1st International Multi-Disciplinary Conference Theme: Sustainable Development and Smart Planning, IMDC-SDSP 2020, Cyperspace, 28-30 June 202* (p. 355). European Alliance for Innovation.
- [19] Duffy, M. A., Hernandez-Santiago, V., Orange, G., Davey, P. G., & Guthrie, B. (2013). Trimethoprim prescription and subsequent resistance in childhood urinary infection: multilevel modelling analysis. *British journal of general practice*, 63(609), e238-e243.
- [20] Navarro, M., Espinosa, L., de las Heras, J. A., Meseguer, G., Peña, M. A., & Larrauri, M. (1984). Symptomatic urinary infection in infants less than 4 months old: outcome in 129 cases. *Anales Espanoles de Pediatria*, 21(6), 564-572.
- [21] Lazar, J. D., & Hilligoss, D. M. (1990, June). The clinical pharmacology of Fluconazole. In *Seminars in Oncology* (Vol. 17, No. 3 Suppl 6, pp. 14-18).

- [22] Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018). Changes in the epidemiological landscape of invasive candidiasis. *Journal of Antimicrobial Chemotherapy*, 73(suppl_1), i4-i13..
- [23] Schrevels, S., & Sanglard, D. (2021). Investigating *Candida glabrata* Urinary Tract Infections (UTIs) in Mice Using Bioluminescence Imaging. *Journal of Fungi*, 7(10), 844.
- [24] Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019, March). Twenty years of the SENTRY antifungal surveillance program: results for *Candida* species from 1997–2016. In *Open forum infectious diseases* (Vol. 6, No. Supplement_1, pp. S79-S94). US: Oxford University Press.
- [25] Ahmed, S. A., Ali, G. M., Sultan, S. M., & Hammed, A. E. (2021). Evaluation of serum level of trace elements (iron, zinc) in patients with celiac disease (Review study). *NTU Journal of Pure Sciences*, 1(1), 27-37.
- [26] Sultan, S., Abed, F. N. M., & Irzoqy, M. E. (2022). Mr Removal some types of heavy metals using kind bio-fungi. *NTU Journal of Renewable Energy*, 2(1), 34-38.
- [27] Roemer, T., & Krysan, D. J. (2014). Antifungal drug development: challenges, unmet clinical needs, and new approaches. *Cold Spring Harbor perspectives in medicine*, 4(5), a019703